Shelby D. Reed, PhD, is a professor in population health sciences at the Duke University School of Medicine. She works primarily at the Duke Clinical Research Institute. Dr. Reed holds a PhD in pharmaceutical health services research from the University of Maryland School of Pharmacy and completed a 2-year postdoctoral fellowship in the Pharmaceutical Outcomes Research and Policy Program and the Center for AIDS Research at the University of Washington. Dr. Reed has nearly 20 years of experience in economic evaluation, health services research and health policy. Dr. Reed has extensive expertise in designing and conducting trial-based and model-based cost-effectiveness analyses of medical diagnostics and interventions in numerous therapeutic areas. She was a member of the ISPOR Task Forces that published recommendations for Good Research Practices for Cost-Effectiveness Analysis Alongside Clinical Trials in 2005 and 2015. She has led a wide range of economic and epidemiological studies using secondary data from health care claims, clinical trials, surveys and disease registries. In her evaluations of health policy issues, she has developed computer models to analyze the potential economic impact of trends in clinical trial design, changes in reimbursement policies, financial incentives and the regulatory process in the development of orphan drugs, and the societal value of alternative approaches to identifying drug safety problems. Over the last several years, her research has increasingly focused on stated-preference studies to evaluate benefit-risk tradeoffs, patient-centered value, and their application in comparative effectiveness research and clinical decision making.
Dong OM, Poonnen PJ, Winski D, Reed SD, Vashistha V, Bates J, et al. Cost-Effectiveness of Tumor Genomic Profiling to Guide First-Line Targeted Therapy Selection in Patients With Metastatic Lung Adenocarcinoma. Value Health. 2022 Apr;25(4):582–94.
Hung A, Li Y, Candelieri D, Alba P, Anglin-Foote T, Lee KM, et al. Factors associated with gene mutation testing in United States veterans with metastatic castration-resistant prostate cancer. In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2022. p. 47–47.
Chew DS, Li Y, Zeitouni M, Whellan DJ, Kitzman D, Mentz RJ, et al. Economic Outcomes of Rehabilitation Therapy in Older Patients With Acute Heart Failure in the REHAB-HF Trial: A Secondary Analysis of a Randomized Clinical Trial. Jama Cardiol. 2022 Feb 1;7(2):140–8.